首页> 外文OA文献 >Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

【2h】

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

机译：抗体 - 药物缀合物，GSK2857916，复发/难治性多发性骨髓瘤：我研究的剂量扩张阶段的安全性和疗效的更新

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Suzanne Trudel; Nikoletta Lendvai; Rakesh Popat; Peter M. Voorhees; Brandi Reeves; Edward N. Libby; Paul G. Richardson; Axel Hoos; Ira Gupta; Veronique Bragulat; Zangdong He; Joanna B. Opalinska; Adam D. Cohen;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study [J] . Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Blood cancer journal. . 2019,第4期

机译：抗体/药物偶联物GSK2857916在复发/难治性多发性骨髓瘤中的应用：剂量扩展I期研究的安全性和有效性更新
2. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial [J] . Trudel Suzanne, Lendvai Nikoletta, Popat Rakesh, The lancet oncology . 2018,第12期

机译：用GSK2857916抗体 - 药物缀合物靶向B细胞成熟抗原，在复发或难以多发性骨髓瘤（BMA117159）：剂量升级和膨胀阶段1试验
3. First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation [J] . Cohen Adam D., Popat Rakesh, Trudel Suzanne, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：首先在与GSK2857916进行的人类研究中，将与微管破坏剂缀合的抗体药物，其针对复发/难治多骨髓瘤（MM）的患者中针对B细胞成熟抗原（BCMA）的抗原（BCMA）：研究BMA117159部分1剂量升级
4. Investigation of Anti-Drug-Antibody Impact on LC-MS/MS Bioanalysis of Unconjugated Payload of Antibody Drug Conjugate in a Monkey Study [C] . Hang Zeng, Ragu Ramanathan, Frank Barletta, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：对猴子研究中的抗体药物缀合物未缀合有效载荷的LC-MS / MS生物分析的抗药物 - 抗体的影响
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Antibody–drug conjugate GSK2857916 in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study [O] . Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, 2019

机译：抗体/药物偶联物GSK2857916在复发/难治性多发性骨髓瘤中的应用：剂量扩展I期研究的安全性和有效性更新
7. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma [O] . A. Keith Stewart, Amrita Y. Krishnan, Seema Singhal, 2019

机译：I阶段I研究抗FCRH5抗体 - 药物缀合物DFRF4539A复发或难治性多发性骨髓瘤

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

著录项

引文网络

相似文献

相关主题

期刊订阅